Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avian Influenza
Avian influenza vaccine well tolerated in patients
March 24th, 2006
CSL Limited, an Australian biopharmaceutical company, has encouraging preliminary results of its initial clinical trial of a pandemic influenza vaccine, based on the H5N1 avian virus. The Australian trial, conducted at the Murdoch Children's Research Institute in conjunction with Melbourne University and the Royal Adelaide Hospital, has shown the candidate vaccine to be well tolerated in the study population. Importantly it confirmed that when used in conjunction with a stimulant, or adjuvant, two standard doses of the vaccine will create an appropriate human immunological response in a significant number of volunteers. "We have learned three very...
Source: Drug Week (2006-03-24)
|
